Abbott Laboratories (ABT) is facing new regulatory uncertainty after Indian authorities launched an investigation into its supply chain, Abbott Healthcare, concerning the alleged misuse and diversion of codeine-based cough syrup. This scrutiny adds pressure following the company's recent disappointing Q4 2025 sales miss and outlook.
- The investigation centers specifically on the alleged misuse and diversion of codeine-based cough syrup products.
- Shares continued to decline following the regulatory news, closing at $107.42 (-1.10%) on January 23.